MX2024005109A - Nanoparticulas lipidicas para administracion de oligonucleotidos. - Google Patents
Nanoparticulas lipidicas para administracion de oligonucleotidos.Info
- Publication number
- MX2024005109A MX2024005109A MX2024005109A MX2024005109A MX2024005109A MX 2024005109 A MX2024005109 A MX 2024005109A MX 2024005109 A MX2024005109 A MX 2024005109A MX 2024005109 A MX2024005109 A MX 2024005109A MX 2024005109 A MX2024005109 A MX 2024005109A
- Authority
- MX
- Mexico
- Prior art keywords
- lipid nanoparticles
- lipid
- oligonucleotide delivery
- formula
- compound according
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
- C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/28—Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/5123—Organic compounds, e.g. fats, sugars
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6018—Lipids, e.g. in lipopeptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Optics & Photonics (AREA)
- Physics & Mathematics (AREA)
- Biomedical Technology (AREA)
- Nanotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21205904 | 2021-11-02 | ||
| EP22179399 | 2022-06-16 | ||
| PCT/EP2022/080581 WO2023078950A1 (en) | 2021-11-02 | 2022-11-02 | Lipid nanoparticles for oligonucleotide delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2024005109A true MX2024005109A (es) | 2024-05-31 |
Family
ID=84364268
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2024005109A MX2024005109A (es) | 2021-11-02 | 2022-11-02 | Nanoparticulas lipidicas para administracion de oligonucleotidos. |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20250236599A1 (https=) |
| EP (2) | EP4613741A3 (https=) |
| JP (1) | JP2024540108A (https=) |
| KR (1) | KR20240099377A (https=) |
| AU (1) | AU2022381463A1 (https=) |
| CA (1) | CA3236653A1 (https=) |
| DK (1) | DK4426270T3 (https=) |
| ES (1) | ES3042660T3 (https=) |
| FI (1) | FI4426270T3 (https=) |
| IL (1) | IL312432B1 (https=) |
| MX (1) | MX2024005109A (https=) |
| PL (1) | PL4426270T3 (https=) |
| WO (1) | WO2023078950A1 (https=) |
| ZA (1) | ZA202403360B (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12491261B2 (en) | 2016-10-26 | 2025-12-09 | Acuitas Therapeutics, Inc. | Lipid nanoparticle formulations |
| CA3116576A1 (en) | 2018-10-18 | 2020-04-23 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
| CN118125994A (zh) * | 2022-11-25 | 2024-06-04 | 艾斯拓康医药科技(北京)有限公司 | 可离子化脂质及其应用 |
| WO2024136309A1 (en) * | 2022-12-23 | 2024-06-27 | Green Cross Corporation | Ionizable lipid and use thereof |
| CN116514696B (zh) * | 2023-06-29 | 2023-12-01 | 艾斯拓康医药科技(北京)有限公司 | 可离子化脂质及其应用 |
| WO2025088152A1 (en) | 2023-10-27 | 2025-05-01 | Ziphius Nv | MODIFIED 5'UTRs |
| US12599560B2 (en) | 2023-11-02 | 2026-04-14 | Longuide Biopharma Corporation | Lipids and lipid nanoparticle formulations |
| WO2025104023A1 (en) | 2023-11-13 | 2025-05-22 | Ziphius Nv | MODIFIED ALPHAVIRAL nsP3 |
| WO2025128696A1 (en) * | 2023-12-12 | 2025-06-19 | Acuitas Therapeutics, Inc. | Cationic lipid compounds for use in lipid nanoparticles |
| WO2025255534A1 (en) * | 2024-06-07 | 2025-12-11 | Innovac Therapeutics Hk Limited | Diol-based novel ionizable lipids and their uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
| CN1989250B (zh) | 2004-05-18 | 2013-11-20 | 阿尔法瓦克斯公司 | Tc-83衍生的甲病毒属载体、颗粒和方法 |
| US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
| WO2014028487A1 (en) * | 2012-08-13 | 2014-02-20 | Massachusetts Institute Of Technology | Amine-containing lipidoids and uses thereof |
| WO2018232120A1 (en) * | 2017-06-14 | 2018-12-20 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
-
2022
- 2022-11-02 PL PL22813505.9T patent/PL4426270T3/pl unknown
- 2022-11-02 JP JP2024525411A patent/JP2024540108A/ja active Pending
- 2022-11-02 DK DK22813505.9T patent/DK4426270T3/da active
- 2022-11-02 WO PCT/EP2022/080581 patent/WO2023078950A1/en not_active Ceased
- 2022-11-02 FI FIEP22813505.9T patent/FI4426270T3/fi active
- 2022-11-02 ES ES22813505T patent/ES3042660T3/es active Active
- 2022-11-02 MX MX2024005109A patent/MX2024005109A/es unknown
- 2022-11-02 CA CA3236653A patent/CA3236653A1/en active Pending
- 2022-11-02 IL IL312432A patent/IL312432B1/en unknown
- 2022-11-02 EP EP25189933.2A patent/EP4613741A3/en active Pending
- 2022-11-02 AU AU2022381463A patent/AU2022381463A1/en active Pending
- 2022-11-02 EP EP22813505.9A patent/EP4426270B1/en active Active
- 2022-11-02 KR KR1020247018058A patent/KR20240099377A/ko active Pending
- 2022-11-02 US US18/705,479 patent/US20250236599A1/en active Pending
-
2024
- 2024-04-30 ZA ZA2024/03360A patent/ZA202403360B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4613741A2 (en) | 2025-09-10 |
| EP4426270B1 (en) | 2025-07-23 |
| US20250236599A1 (en) | 2025-07-24 |
| IL312432B1 (en) | 2026-01-01 |
| EP4426270A1 (en) | 2024-09-11 |
| JP2024540108A (ja) | 2024-10-31 |
| KR20240099377A (ko) | 2024-06-28 |
| WO2023078950A1 (en) | 2023-05-11 |
| IL312432A (en) | 2024-06-01 |
| ES3042660T3 (en) | 2025-11-24 |
| FI4426270T3 (fi) | 2025-09-12 |
| DK4426270T3 (da) | 2025-09-22 |
| PL4426270T3 (pl) | 2025-11-24 |
| AU2022381463A1 (en) | 2024-05-16 |
| EP4613741A3 (en) | 2025-11-12 |
| ZA202403360B (en) | 2025-08-27 |
| CA3236653A1 (en) | 2023-05-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202403360B (en) | Lipid nanoparticles for oligonucleotide delivery | |
| ZA202403337B (en) | Lipid nanoparticles for oligonucleotide delivery | |
| BR112022013599A2 (pt) | Nanomateriais | |
| ZA202306901B (en) | Ionizable lipids | |
| ZA202309527B (en) | Ionizable lipids and compositions for nucleic acid delivery | |
| AU2016343803A8 (en) | Novel lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| MY202837A (en) | Lipids for lipid nanoparticle delivery of active agents | |
| PH12021500045A1 (en) | Ionizable amine lipids and lipid nanoparticles | |
| EP4420679A3 (en) | Lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| ZA202103233B (en) | Lipid nanoparticle formulations | |
| EP4310075A3 (en) | Ionizable cationic lipid for rna delivery | |
| EP4344702A3 (en) | Pyrazolyl derivatives useful as anti-cancer agents | |
| WO2019036008A8 (en) | Lipids for use in lipid nanoparticle formulations | |
| MX2020000268A (es) | Agonista de fxr. | |
| EP4410317A3 (en) | Novel carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids | |
| MX2024015149A (es) | Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos | |
| MX2019000566A (es) | Suministro mediado por ve de conjugados de proteína de enlace-molécula pequeña. | |
| MX2024005714A (es) | Lípidos catiónicos ionizables para la administración de arn. | |
| MX348474B (es) | Lipidos, composiciones de lipido, y metodos de uso de los mismos. | |
| WO2023114937A3 (en) | Fluorinated cationic lipids for use in lipid nanoparticles | |
| WO2013188792A3 (en) | Neuroactive steroids, compositions, and uses thereof | |
| EP3693369A3 (en) | Bromodomain inhibitors | |
| MX2025002671A (es) | Lipidos para uso en formulaciones de nanoparticulas de lipidos | |
| MX338685B (es) | Formulaciones de solucion intravenosa de posaconacol estabilizadas mediante beta-ciclodextrina sustituida. | |
| CR20230413A (es) | Moduladores de sting (estimulador de genes de interferón) |